{"id":24461,"date":"2022-11-09T16:20:00","date_gmt":"2022-11-09T08:20:00","guid":{"rendered":"https:\/\/flcube.com\/?p=24461"},"modified":"2025-01-31T16:23:36","modified_gmt":"2025-01-31T08:23:36","slug":"merck-kgaa-collaborates-with-biotheus-to-accelerate-cell-line-characterization","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=24461","title":{"rendered":"Merck KGaA Collaborates with Biotheus to Accelerate Cell Line Characterization"},"content":{"rendered":"\n

German pharmaceutical giant Merck KGaA (ETR: MRK<\/a>) has announced a collaboration with Biotheus, a China-based biotech company focused on developing treatments for cancer and autoimmune diseases. The partnership aims to streamline Biotheus’ development process by utilizing Merck\u2019s Blazar Rodent Panel, which significantly reduces the turn-around-time (TAT) of cell line characterization from around 60 days to just 14 days.<\/p>\n\n\n\n

Blazar Rodent Panel Profile<\/strong>
Launched in the third quarter of 2020, the Blazar Rodent Panel is a cutting-edge technology that detects a much broader range of adventitious viruses compared to traditional Polymerase Chain Reaction (PCR) methods. By targeting conserved regions within virus families, the panel allows the biopharma industry to move away from traditional animal experiments for detecting rodent-origin viruses in cell banks used in the production of biologics.<\/p>\n\n\n\n

Impact on Biotheus’ Development<\/strong>
“The Blazar Rodent Panel from Merck is one of the few technologies available on the market that will empower us in expediting approvals for IND and BLA in China and beyond,” said Xu Yingda, Vice President of Chemical Manufacturing and Control at Biotheus Inc. This collaboration underscores Merck KGaA’s commitment to supporting innovative biotech companies and accelerating the development of critical therapies.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

German pharmaceutical giant Merck KGaA (ETR: MRK) has announced a collaboration with Biotheus, a China-based…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[774,1147,120],"class_list":["post-24461","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotheus","tag-etr-mrk","tag-merck"],"yoast_head":"\nMerck KGaA Collaborates with Biotheus to Accelerate Cell Line Characterization - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"German pharmaceutical giant Merck KGaA (ETR: MRK) has announced a collaboration with Biotheus, a China-based biotech company focused on developing treatments for cancer and autoimmune diseases. The partnership aims to streamline Biotheus' development process by utilizing Merck\u2019s Blazar Rodent Panel, which significantly reduces the turn-around-time (TAT) of cell line characterization from around 60 days to just 14 days.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=24461\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck KGaA Collaborates with Biotheus to Accelerate Cell Line Characterization\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=24461\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-09T08:20:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-31T08:23:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24461#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24461\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Merck KGaA Collaborates with Biotheus to Accelerate Cell Line Characterization\",\"datePublished\":\"2022-11-09T08:20:00+00:00\",\"dateModified\":\"2025-01-31T08:23:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24461\"},\"wordCount\":206,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotheus\",\"ETR: MRK\",\"Merck\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24461#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24461\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=24461\",\"name\":\"Merck KGaA Collaborates with Biotheus to Accelerate Cell Line Characterization - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-11-09T08:20:00+00:00\",\"dateModified\":\"2025-01-31T08:23:36+00:00\",\"description\":\"German pharmaceutical giant Merck KGaA (ETR: MRK) has announced a collaboration with Biotheus, a China-based biotech company focused on developing treatments for cancer and autoimmune diseases. The partnership aims to streamline Biotheus' development process by utilizing Merck\u2019s Blazar Rodent Panel, which significantly reduces the turn-around-time (TAT) of cell line characterization from around 60 days to just 14 days.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24461#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24461\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24461#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck KGaA Collaborates with Biotheus to Accelerate Cell Line Characterization\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck KGaA Collaborates with Biotheus to Accelerate Cell Line Characterization - Insight, China's Pharmaceutical Industry","description":"German pharmaceutical giant Merck KGaA (ETR: MRK) has announced a collaboration with Biotheus, a China-based biotech company focused on developing treatments for cancer and autoimmune diseases. The partnership aims to streamline Biotheus' development process by utilizing Merck\u2019s Blazar Rodent Panel, which significantly reduces the turn-around-time (TAT) of cell line characterization from around 60 days to just 14 days.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=24461","og_locale":"en_US","og_type":"article","og_title":"Merck KGaA Collaborates with Biotheus to Accelerate Cell Line Characterization","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=24461","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-11-09T08:20:00+00:00","article_modified_time":"2025-01-31T08:23:36+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=24461#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=24461"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Merck KGaA Collaborates with Biotheus to Accelerate Cell Line Characterization","datePublished":"2022-11-09T08:20:00+00:00","dateModified":"2025-01-31T08:23:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=24461"},"wordCount":206,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotheus","ETR: MRK","Merck"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=24461#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=24461","url":"https:\/\/flcube.com\/?p=24461","name":"Merck KGaA Collaborates with Biotheus to Accelerate Cell Line Characterization - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-11-09T08:20:00+00:00","dateModified":"2025-01-31T08:23:36+00:00","description":"German pharmaceutical giant Merck KGaA (ETR: MRK) has announced a collaboration with Biotheus, a China-based biotech company focused on developing treatments for cancer and autoimmune diseases. The partnership aims to streamline Biotheus' development process by utilizing Merck\u2019s Blazar Rodent Panel, which significantly reduces the turn-around-time (TAT) of cell line characterization from around 60 days to just 14 days.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=24461#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=24461"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=24461#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Merck KGaA Collaborates with Biotheus to Accelerate Cell Line Characterization"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24461","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24461"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24461\/revisions"}],"predecessor-version":[{"id":24462,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24461\/revisions\/24462"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24461"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24461"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24461"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}